StreetInsider.com News Articles

Form 8-K MANGOCEUTICALS, INC. For: Oct 08

Fri, 09 Oct 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20261009/27171467.html

Mangoceuticals closes $500K offering at 74% premium to recent price

Fri, 09 Oct 2026 16:01:24 -0400

Mangoceuticals, Inc. (NASDAQ: MGRX) closed a registered direct offering of approximately $500,000 on Oct. 9, 2026, priced at $0.75 per unit, representing a 74% premium to the company's referenced recent closing share price of $0.43.

Each unit consists of one share of common stock and one warrant. The offering was conducted with a U.S.-based private investment firm under an effective shelf registration statement on Form S-3 previously declared effective by the SEC on June 24, 2025.

The transaction follows a separate subsidiary-level financing announced Oct. 1, 2026, in which MangoRx IP Holdings, LLC, a subsidiary of Mangoceuticals, entered into agreements for $2.5

Mangoceuticals Closes Registered Direct Offering Priced at 74% Premium to Recent Market Close

Fri, 09 Oct 2026 16:01:00 -0400

Transaction follows a $2.5 million strategic investment commitment at MangoRx IP Holdings to support intellectual property commercialization

DALLAS, TX, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”), a company focused on developing, marketing and selling health and wellness products through its telemedicine platforms under the MangoRx and PeachesRx brands, today announced the closing of a registered direct offering with a U.S.-based private investment firm, priced at a premium to the Company’s recent closing share price. Management believes the transaction reflects investor interest in the Company’s strategy and long-term opportunities.

Mangoceuticals Closes Registered Direct Offering Priced at 74% Premium to Recent Market Close

Fri, 09 Oct 2026 16:01:00 -0400

Transaction follows a $2.5 million strategic investment commitment at MangoRx IP Holdings to support intellectual property commercialization

Form 424B5 MANGOCEUTICALS, INC.

Fri, 09 Oct 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20261009/27171438.html

Form 4 MANGOCEUTICALS, INC. For: Jul 28 Filed by: Hamilton Alex P.

Tue, 06 Oct 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20261006/27152118.html

Form SCHEDULE 13D/A MANGOCEUTICALS, INC. Filed by: Cohen Jacob D.

Tue, 06 Oct 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20261006/27152133.html

Form 4 MANGOCEUTICALS, INC. For: Sep 30 Filed by: Cohen Jacob D.

Tue, 06 Oct 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20261006/27152158.html

Form 4 MANGOCEUTICALS, INC. For: Jul 28 Filed by: JOHNSTON EUGENE M

Tue, 06 Oct 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20261006/27152171.html

Form 8-K MANGOCEUTICALS, INC. For: Sep 30

Thu, 01 Oct 2026 15:51:00 -0400

si-local-file:///var/storage/secattach/20261001/27135621.html

Mangoceuticals raises $2.5M via subsidiary stake sale, no new shares

Thu, 01 Oct 2026 15:50:19 -0400

Mangoceuticals, Inc. (NASDAQ: MGRX) announced that its former wholly-owned subsidiary, MangoRx IP Holdings, LLC, has entered into subscription agreements with two investors for a combined $2.5 million investment, with an initial tranche of $1.75 million already received.

The investment is structured at the subsidiary level and does not involve the issuance of any Mangoceuticals common stock, warrants, or other securities of the parent company, leaving the company's public capitalization structure unchanged.

Under the terms of the agreements, the two investors will acquire a combined 25% membership interest in MangoRx IP Holdings. The initial $1.75 million purchases a 17.5% membership interest, with the

Mangoceuticals Secures $2.5 Million Strategic Investment in MangoRx IP Holdings; Receives Initial $1.75 Million Tranche

Thu, 01 Oct 2026 15:50:00 -0400

Subsidiary-Level Investment Provides Capital to Advance Commercialization of the Company’s Antiviral Intellectual Property Portfolio with No Issuance of MGRX Common Stock

DALLAS, TEXAS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”), a company focused on developing, marketing, and selling health and wellness products through a secure telemedicine platform under the brands MangoRx and PeachesRx, today announced that its former wholly-owned subsidiary, MangoRx IP Holdings, LLC (“MangoRx IP”), has entered into subscription agreements with two strategic investors for an aggregate investment of $2.5 million directly into MangoRx IP, and has

Mangoceuticals Secures $2.5 Million Strategic Investment in MangoRx IP Holdings; Receives Initial $1.75 Million Tranche

Thu, 01 Oct 2026 15:50:00 -0400

Subsidiary-Level Investment Provides Capital to Advance Commercialization of the Company’s Antiviral Intellectual Property Portfolio with No Issuance of MGRX Common Stock

Form 8-K MANGOCEUTICALS, INC. For: Aug 19

Fri, 21 Aug 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260821/26962459.html

Form 8-K MANGOCEUTICALS, INC. For: Aug 19

Fri, 21 Aug 2026 17:15:00 -0400

si-local-file:///var/storage/secattach/20260821/26962459.html

Form 10-Q MANGOCEUTICALS, INC. For: Jun 30

Thu, 13 Aug 2026 17:28:00 -0400

si-local-file:///var/storage/secattach/20260813/26922877.html

Form 10-Q MANGOCEUTICALS, INC. For: Jun 30

Thu, 13 Aug 2026 17:28:00 -0400

si-local-file:///var/storage/secattach/20260813/26922877.html

Form 425 MANGOCEUTICALS, INC. Filed by: MANGOCEUTICALS, INC.

Thu, 13 Aug 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260813/26921611.html

Form 425 MANGOCEUTICALS, INC. Filed by: MANGOCEUTICALS, INC.

Thu, 13 Aug 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260813/26921611.html

Nuclea Energy agrees to buy Moltex Energy's nuclear technology assets

Thu, 13 Aug 2026 16:07:15 -0400

Nuclea Energy Inc., an advanced nuclear technology company based in Mississauga, Ontario, announced that its wholly owned subsidiary, Nuclea Energy Canada Inc., has entered into a definitive agreement to acquire technology assets from Moltex Energy Limited, which is currently in administration.

The asset acquisition targets intellectual property and development materials associated with Moltex's Stable Salt Reactor-Wasteburner (SSR-W), a 300–500 MWe advanced molten salt fast reactor, and its Waste To Stable Salt (WATSS) spent nuclear fuel recycling process. The portfolio also includes 80 patents across nine patent families and nine pending patents related to the fuel recycling process.

The target portfolio was developed

Nuclea Energy agrees to buy Moltex nuclear technology assets

Thu, 13 Aug 2026 16:05:43 -0400

Nuclea Energy, Inc., the merger partner of Mangoceuticals, Inc. (NASDAQ: MGRX), has signed a definitive agreement to acquire advanced nuclear technology assets from Moltex Energy Limited, which is currently in administration, according to a press release issued by Mangoceuticals.

The transaction, structured principally as an asset acquisition, targets intellectual property and development materials associated with Moltex's Stable Salt Reactor–Wasteburner (SSR-W), a 300–500 MWe molten salt fast reactor, and its Waste To Stable Salt (WATSS) spent nuclear fuel recycling process. The portfolio also includes a FLEX reactor design and a patent portfolio comprising 80 patents across nine patent families, plus nine pending

Nuclea Energy, Enters into Definitive Agreement to Acquire Moltex Energy's Advanced Nuclear Technology Assets

Thu, 13 Aug 2026 16:05:00 -0400

The acquisition of Moltex brings over a decade of advanced nuclear R&D, backed by more than C$96 million in private investment and public funding from Canada and the U.S. Department of Energy.

Asset-led transaction to add intellectual property and development materials related principally to the SSR-W advanced reactor and WATSS spent nuclear fuel recycling technologies.

Mississauga, Ontario--(Newsfile Corp. - August 13, 2026) - Nuclea Energy Inc. ("Nuclea" or the "Company"), an advanced nuclear technology company headquartered in Mississauga, Ontario, developing the Morpheus microreactor, a lead-cooled, factory-built micro-modular reactor, today announces that its wholly owned subsidiary, Nuclea Energy Canada Inc. ("Nuclea Canada"), has

Nuclea Energy, Enters into Definitive Agreement to Acquire Moltex Energy's Advanced Nuclear Technology Assets

Thu, 13 Aug 2026 16:05:00 -0400

The acquisition of Moltex brings over a decade of advanced nuclear R&D, backed by more than C$96 million in private investment and public funding from Canada and the U.S. Department of Energy.

Asset-led transaction to add intellectual property and development materials related principally to the SSR-W advanced reactor and WATSS spent nuclear fuel recycling technologies.

Mangoceuticals Inc.’s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy’s Advanced Nuclear Technology Assets

Thu, 13 Aug 2026 16:05:00 -0400

The acquisition of Moltex brings over a decade of advanced nuclear R&D, backed by more than C$96 million in private investment and public funding from Canada and the U.S. Department of Energy.

Asset-led transaction to add intellectual property and development materials related principally to the SSR-W advanced reactor and WATSS spent nuclear fuel recycling technologies.

DALLAS, Texas, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”) today announced that its merger partner, Nuclea Energy, Inc. (“Nuclea”), an advanced nuclear technology company headquartered in Mississauga, Ontario, developing the Morpheus

Mangoceuticals Inc.’s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy’s Advanced Nuclear Technology Assets

Thu, 13 Aug 2026 16:05:00 -0400

The acquisition of Moltex brings over a decade of advanced nuclear R&D, backed by more than C$96 million in private investment and public funding from Canada and the U.S. Department of Energy.

Asset-led transaction to add intellectual property and development materials related principally to the SSR-W advanced reactor and WATSS spent nuclear fuel recycling technologies.